Targeting the cause of neurodegenerative and autoimmune diseases

June 2019
Disclaimer

This presentation has been prepared by GeNeuro solely for use in the context of a general information meeting. All persons accessing this document must agree to the restrictions and limitations set out below. This material is given in conjunction with an oral presentation and should not be taken out of context.

This presentation has been prepared for information and background purposes only and the information contained herein (unless otherwise indicated) has been prepared by GeNeuro S.A. (the “Company”). It includes only summary information and does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris. No reliance may be placed for any purposes whatsoever on the information or opinions contained in this document or on its accuracy or completeness.

This presentation includes “forward-looking statements.” Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of the Company as of the date indicated and are subject to change without notice. All information not separately sourced is from internal Company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is not intended to predict actual results, and no assurances are given with respect thereto. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as of the date of this presentation. Investors are urged to consider these factors carefully in evaluating the forward-looking statements in this presentation and not to place undue reliance on such statements.

The information contained in this presentation has not been independently verified and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of the Company or any of its affiliates, advisers, connected persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation.

Any securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States absent registration under the Securities Act or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The distribution of this presentation may be restricted by law in certain jurisdictions, and persons into whose possession these materials come should inform themselves about, and observe, any such restrictions. No public offering of securities is being made in the United States or any other jurisdiction.
GeNeuro’s mission

To develop therapies that improve the life of patients with neurodegenerative and autoimmune diseases

• Leveraging the biology of human endogenous retroviruses (HERVs) to stop causal factors associated with these disorders

• The HERV field is a new frontier pioneered by GeNeuro since 2006, based on 15 years of R&D at Institut Mérieux and INSERM

• Approach validated through results on Multiple Sclerosis disease progression markers in a Phase IIb clinical trial
Recent data validates GeNeuro’s platform approach against pathogenic HERV proteins

• Positive results of temelimab 1 year 270-patient RRMS Phase IIb and its 1 year extension
  • Consistent benefit with temelimab at highest dose on the key markers of neurodegeneration linked to disease progression
  • At two years, first encouraging signs of dose-dependent effects on clinical measures of disease progression
  • Observed effects independent of inflammatory activity of the patients, confirming direct neuroprotective mode of action
  • Results strongly supported by preclinical evidence and mode of action rationale

➢ Clear positioning against non-active progression, key unmet medical need in MS

• Successful Phase IIa of temelimab in T1D
• Preclinical development of new anti-pHERV-K monoclonal antibody as treatment option for ALS, in partnership with the NIH
• Wide application potential in other autoimmune and degenerative diseases
# First mover in HERV-mediated diseases

<table>
<thead>
<tr>
<th>Program</th>
<th>Pre-clinical</th>
<th>Phase I</th>
<th>Phase IIa</th>
<th>Phase IIb</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Temelimab</strong>&lt;br&gt;Multiple Sclerosis</td>
<td>Planning next stage developments based on positive neurodegeneration 96-week results</td>
<td><img src="change-1" alt="270 patients / 50 centers" /> in the RRMS indication / Completed March 2018</td>
<td><img src="change-2" alt="219 patients extension of CHANGE-MS" />/ Completed March 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHANGE-MS</td>
<td><img src="change-1" alt="270 patients / 50 centers" /> in the RRMS indication / Completed March 2018</td>
<td><img src="change-2" alt="219 patients extension of CHANGE-MS" />/ Completed March 2019</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANGEL-MS</td>
<td><img src="change-1" alt="270 patients / 50 centers" /> in the RRMS indication / Completed March 2018</td>
<td><img src="change-2" alt="219 patients extension of CHANGE-MS" />/ Completed March 2019</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3. Temelimab</strong>&lt;br&gt;Type 1 Diabetes</td>
<td>Safety &amp; signal finding Phase IIa</td>
<td><img src="change-1" alt="270 patients / 50 centers" /> in the RRMS indication / Completed March 2018</td>
<td><img src="change-2" alt="219 patients extension of CHANGE-MS" />/ Completed March 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td><img src="change-1" alt="270 patients / 50 centers" /> in the RRMS indication / Completed March 2018</td>
<td><img src="change-2" alt="219 patients extension of CHANGE-MS" />/ Completed March 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>4. Temelimab</strong>&lt;br&gt;CIDP</td>
<td>ODD granted by the US FDA</td>
<td>Planning discussions with FDA to design a proof-of-concept study</td>
<td><img src="change-1" alt="270 patients / 50 centers" /> in the RRMS indication / Completed March 2018</td>
<td><img src="change-2" alt="219 patients extension of CHANGE-MS" />/ Completed March 2019</td>
<td></td>
</tr>
<tr>
<td><strong>5. Anti-HERV-K</strong>&lt;br&gt;ALS</td>
<td>R&amp;D Agreement with NIH, IND submission planned by mid-2020</td>
<td><img src="change-1" alt="270 patients / 50 centers" /> in the RRMS indication / Completed March 2018</td>
<td><img src="change-2" alt="219 patients extension of CHANGE-MS" />/ Completed March 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>6. New anti HERV-W Ab</strong>&lt;br&gt;Inflammatory Psychosis</td>
<td>Research collaborations with Academic labs</td>
<td><img src="change-1" alt="270 patients / 50 centers" /> in the RRMS indication / Completed March 2018</td>
<td><img src="change-2" alt="219 patients extension of CHANGE-MS" />/ Completed March 2019</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

June 2019
Human Endogenous Retroviruses (HERVs)
Ancestral retroviral genomic (DNA) insertions

HERV elements are latent in human genome
• Represent approximately 8% of total human genome
• Genetic transposition leads to variable copy number, with non-ubiquitous copies in individuals
• HERVs are normally latent but may be de-repressed and transcribed to produce viral proteins

Missing link between viral infections and poorly understood autoimmune / neurodegenerative diseases
• Strong epidemiology data associates environmental viruses with diseases such as MS and T1D
• Environmental viruses do not appear to play a direct role in disease development
• They can activate HERV genes upon infection of permissive cells
• Pathogenic HERV proteins have been suggested as potential causal factors in autoimmune / neurodegenerative diseases

Sources:
Regulatory evolution of innate immunity through co-option of endogenous retroviruses; Science, Vol. 351, Issue 6277
Discovery of unfixed endogenous retrovirus insertions in diverse human populations. Proc Natl Acad Sci U S A. 2016
Human Endogenous Retrovirus Type W Envelope Protein Inhibits Oligodendroglial Precursor Cell Differentiation; Ann Neurol. 2013;74(5)A
Viruses triggering HERV Proteins and link to disease
Examples of pHERV Env mediated diseases

Transactivating viruses in affected organs

- HERV-W
- HERV-K

- Pathogenic HERV proteins found at high levels in affected organs
- Pathogenicity is generally mediated by (abnormally expressed) viral envelope proteins – pHERV Env W, K...
- pHERV Env directed toxicities found in:
  - Microglia
  - OPCs
  - Pancreatic beta islet cells
  - Motor Neurons
  - Schwan cells
  - Others...

CNS Gray Matter
CMV, Toxoplasma...
Inflammatory Psychoses
40-60 % of cases?

CNS White Matter
EBV, HSV1, HHV6, VZV,...
Multiple Sclerosis
75-100% of cases

Motor neurons
Neurotropic viruses,…
Sporadic ALS

Peripheral Nerves
CMV, …
CIDP
~ 50% of cases?

Synovial membrane
?
RA

Pancreas
Enteroviruses,
Coxsackie viruses …
Type 1 Diabetes
50-60 % of cases?

Other Diseases ?
(Systemic lupus,
psoriasis, etc.)

June 2019
Broad and strong IP supporting first mover advantage

- Mérieux Group & GeNeuro worked for more than 25 years in the HERV field
- 16 families of patents in HERV-W*, including the following 3 broad categories:
- **Key granted patents on temelimab filed from 2008 to 2014**
  Strong IP development strategy to continue protecting temelimab beyond 2034 (2039 w. SPC)

**SEP 16 family**
Background including sequences

**TLR4 family**
Antibody strategy against target

**MSRV* ligand family**
Product patents & disease areas

Existing IP portfolio & constant efforts to protect new discoveries place GeNeuro in a strong competitive position

- **New anti pHERV-K patent, co-owned with and in-licensed from NIH**

* previous name of pHERV-W Env

June 2019
Temelimab mode of action in MS
2.5 million MS patients worldwide
$21.8 bn market in 2018

MS is a life-long inflammatory and degenerative disorder of the central nervous system

- Disease onset mainly occurs in young adults
- Female to male ratio is 2:1
- Mean prevalence about 1/1000

Brain impairment
Vision, cognition, motor coordination, equilibrium

Spinal cord impairment
Walking, strength, sensation, sexuality, bowel / bladder control

From the outset of disease, Multiple Sclerosis is marked by neuroinflammation and axonal loss/brain atrophy.

**RRMS**
- Frequent inflammation, demyelination, axonal transection plasticity and remyelination

**SPMS**
- Continuing inflammation, persistent demyelination
- Infrequent inflammation, chronic axonal degeneration gliosis

Inflammation mediated by adaptive immunity (B and T lymphocytes)

Axonal loss
- Neuronal damage mediated by innate immunity (activated microglia)
- and accelerated by hampered remyelination (oligodendrocyte precursor cells)

Adapted from Compston et al., The Lancet 2002

- RRMS: Relapsing-Remitting MS; SPMS: Secondary Progressive MS

June 2019
Known drivers of multiple sclerosis and existing therapeutic agents

Adaptive Immunity

T- and B-cells are selectively recruited to the CNS

Target of most DMTs

- $\alpha$-CD20s mAbs
- $S_1P_{1/n}$ agonists
- $\alpha$-integrin mAb
- etc.

Innate Immunity

CNS resident Microglia

No approved drugs

Repair

Dysfunctional Oligodendrocyte Precursor Cells (OPCs)

No approved drugs

June 2019
Consistent presence of pathogenic HERV-W Envelope protein (pHERV-W Env) in the brains of MS patients

Highly expressed in active MS lesions

- Consistently found in MS brains
- Expression levels correlate with lesion activity
- Present from earliest to latest stages of disease
- Env is predominantly present in microglial/monocytic cells in the MS brain belonging to the innate immune system

pHERV-W Env positive microglial/monocytic cells in MS lesions

Kremer et al., under revision

Sources:

June 2019
pHERV-W Env protein is expressed in progressive MS lesions

- In progressive plaques, pHERV-W Env is expressed in the demyelinating border composed of activated microglia

A - Chronic plaque with microglial line (myelin in brown)

B - The line of microglia is highly activated (HLA-DR+++).

C – pHERV-W Env is expressed in the microglial line only

D - Activated and migrating microglial cells are strongly positive for pHERV-W Env

pHERV-W Env acts on key cells associated with MS disease progression: Microglia and OPCs

pHERV-W Env
- induces an aggressive phenotype (M1) in TLR4+ microglial cells
- activates microglia to associate themselves with myelinated axons
- decreases microglial expression of regenerative factors

fuels microglial-dependent neurodegeneration in MS

pHERV-W Env
- induces release of cytokines & activates NO synthase
- reduces myelin protein expression
- significantly reduces OPC differentiation capacity

drives OPC mediated remyelination failure

Sources: Kremer et al., Ann Neurol 2013; Antony et al., Nat NeuroSci 2004; Madeira et al, JNeuroimmunol 2016; Rolland et al., J Immunol 2006; Kremer et al. presentation at the 2018 Charcot Conference
pHERV-W Env fuels microglial cell mediated neurodegeneration in MS

Microglia activation yields aggressive phenotype

pHERV-W Env activates microglia in neuron / oligodendrocyte co-cultures, leading to axonal injury due to increased TNFα.

- Release of axonal neurofilament light chain (NFL)
- Release of synaptophysin (SYP)

Microglia are directed towards myelinated axons

In neuron / oligodendrocyte / microglia co-cultures pHERV-W Env induces microglia to associate themselves with axonal structures.

Regenerative factors in microglia decreased

Stimulation of microglia with pHERV-W ENV leads to significant decrease of regenerative genes transcription (IGF-1, CSF-1, FGF-2) in microglia.

Source: Kremer, Küry et al. presentation at Charcot Conference, Nov 2018
pHERV-W Env drives OPC mediated remyelination failure

OPCs express increased levels of cytokines & iNOS
pHERV-W Env stimulation of rOPCs *in vitro* leads to a strong induction of iNOS expression. Proinflammatory cytokines such as TNFα, interleukin (IL)-1β, and IL-6 are highly upregulated upon stimulation with pHERV-W Env.

OPC differentiation capacity is significantly reduced
pHERV-W Env markedly decreases number of OPCs expressing early (E) and late (L) markers of myelin:
- 2′,3′-cyclic nucleotide 3′-phosphodiesterase, CNPase, (E)
- Myelin basic protein, MBP, (L)

Source: Kremer et al., Ann Neurol 2013
June 2019
Temelimab (GNbAC1) rescues myelin expression by blocking Env-induced nitrosative stress in OPCs

- Recombinant, humanized IgG4-κ mAb
- PK approx. dose linear, Half-life ≈ 1 month
- Binds with high affinity to pHERV-W Env ($K_d = 2.2 \text{ nM}$)
- Blocks pHERV-W Env activation of TLR4
- Rescues MBP* expression in OPCs

*MBP: Myelin Basic Protein; marker of OPC maturation


June 2019
Temelimab clinical results in MS
Phase IIb trial (CHANGE-MS followed by ANGEL-MS)
Efficacy in RRMS patients at 6 months, 1 year and 2 years

- International, randomized, double-blind, placebo-controlled Phase 2b study in RRMS patients + extension
- Primary Endpoint: Cumulative # Gd+ lesions on brain MRI scans at weeks 12-24
- After 24 weeks, the control group is composed of patients originally randomized to placebo.
- Remyelination and neuroprotection endpoints at 48 weeks and at week 96 in extension study

**CHANGE-MS**
- **Period 1**
  - 6 repeated doses
  - 270 patients (1:1:1:1)
- **Period 2**
  - 6 repeated doses
  - 247 patients (1:1:1)

**ANGEL-MS**
- Secondary endpoints & Full analysis
  - March 2018
- Extension Study
  - Top-line analysis
  - March 2019

- **92% of patients**

**MRI**

Administration: IMP IV every 4 weeks

June 2019

---

**INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B STUDY IN RRMS PATIENTS**

**Primary Endpoint:**
Cumulative # Gd+ lesions on brain MRI scans at weeks 12-24

**After 24 weeks,** the control group is composed of patients originally randomized to placebo.

**Remyelination and neuroprotection endpoints**
at 48 weeks and at week 96 in extension study

**Period 1**
- 6 repeated doses
- 270 patients (1:1:1:1)

**Period 2**
- 6 repeated doses
- 247 patients (1:1:1)

**CHANGE-MS**

**MRI**

Administration: IMP IV every 4 weeks

**Extension Study**

**92% of patients**

---

**INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B STUDY IN RRMS PATIENTS**

**Primary Endpoint:**
Cumulative # Gd+ lesions on brain MRI scans at weeks 12-24

**After 24 weeks,** the control group is composed of patients originally randomized to placebo.

**Remyelination and neuroprotection endpoints**
at 48 weeks and at week 96 in extension study

**Period 1**
- 6 repeated doses
- 270 patients (1:1:1:1)

**Period 2**
- 6 repeated doses
- 247 patients (1:1:1)

**CHANGE-MS**

**MRI**

Administration: IMP IV every 4 weeks

**Extension Study**

**92% of patients**

---
ANGEL-MS: extension study to CHANGE-MS assessing safety & efficacy of temelimab in RRMS patients

- 219 patients from CHANGE-MS entered ANGEL-MS (92% of completers)
  - Early termination was a result of Servier’s decision to opt-out
  - 154 patients (70%) completed 96 weeks or more across the combined studies
  - Approximately 90% of patients completed at least 86 weeks

- All patients remained on active therapy; patients, investigators and MRI reading center remained blinded to dose/original randomization group

- Delays in study start-up led to dose interruptions between the trials
  - > 80% missed ≥ 1 dose; ≈ 50% missed ≥ 2 doses and ≈ 20% missed ≥ 3 doses

- Analysis strategy:
  - As per SAP, original randomization groups: 18, 12 and 6mg/kg & Control Group (defined as patients originally randomized to placebo in CHANGE-MS, and re-randomized to active treatment after 6 months)
  - Several sensitivity analyses performed:
    - (1) by dose groups (placebo patients placed into the active dose group they were re-randomized to)
    - (2) by exposure (separating quartiles by total exposure to temelimab, irrespective of body weight);
    - (3) separating 18mg/kg against all other treatments
  - No adjustments were performed for multiple testing

June 2019
CHANGE-MS and ANGEL-MS 48-week results position temelimab’s against disease progression in MS

- **No clinically relevant benefit on MRI markers of neuroinflammation**
  - Primary endpoint on the reduction of number of Gd+ lesions at Week 24 not met
  - All groups substantially improved from Week 24 to Week 48
  - No significant differences across groups

- **Consistent benefit with temelimab at highest dose on key markers of neurodegeneration, linked to disease progression**
  - Reduction of Brain Atrophy (thalamus, cerebral cortex, deep gray matter and whole brain)
  - Reduction in T1 Black Holes (marker of permanent tissue damage)
  - Benefit seen on Magnetization Transfer Ratio (MTR - measure of remyelination)

- **Temelimab’s effect is independent from the inflammatory activity experienced by the patients during the study**

- **First encouraging signals of neuroprotection translating into clinical benefits at 96 weeks**

- **Continued excellent safety and tolerability**
  - Opens the door for possible increase in dose, and/or
  - Combination with powerful anti-inflammatory agents

June 2019
Clinical data show positive effects of temelimab

1. **Evolution of Cortical Atrophy over 96 weeks**
   - Median % Change From Baseline
   - Control: (1.29) 42%
   - 6mg/kg: (1.27) 41%
   - 18mg/kg: (0.75)
   - Placebo
   - Median reduction at week 48 in ANGEL-MS
   - Relative reduction of atrophy
   - Control: 42%
   - 6mg/kg: 41%
   - 18mg/kg: 0%
   - Dose effect p=0.058

2. **Evolution of Cortical MTR(2) signal over 96 weeks**
   - CC Band 2 (Dose effect p=0.035)
   - CHANGE-MS to ANGEL-MS Week 48
   - Median % reduction at week 48 in ANGEL-MS
   - Median reduction between 18mg/kg group and control group in new larger T1 Black Holes(3) = 63% (p=0.014)

3. **Reduction of Black Holes at week 48 (not computed at week 96 for technical reasons)**
   - Black Holes
   - New larger Black Holes
   - 18mg
   - 12mg
   - 6mg
   - Placebo
   - Median number of lesions (95% CI)
   - Mean Number of Lesions

4. **Very well tolerated drug**
   - # of Patients (%)
   - 18 mg/kg (N=77)
   - 12 mg/kg (N=68)
   - 6 mg/kg (N=74)
   - Adverse Events (AEs)
   - 34 (44.2%)
   - 32 (47.1%)
   - 33 (44.6%)
   - Serious Adverse Events (SAEs)
   - 5 (6.5%)
   - 1 (1.5%)
   - 6 (8.1%)
   - Serious Related AEs
   - 3 (3.9%)
   - 0
   - 0
   - AEs Leading to Study Discontinuation
   - 2 (2.6%)
   - 1 (1.5%)
   - 1 (1.4%)
   - Fatality(4)
   - 1 (1.3%)
   - 0
   - 0

(1) Dose effect analyzed by linear regression, SAS analysis proc GLM; (2) MTR = Magnetization transfer ratio; (3) T1 hypointense lesion ≥ 14mm3 volume; (4) Patient had previously voluntarily exited the study; the Investigator considered the event as unrelated.
Continued reduction Thalamic atrophy
Original CHANGE-MS Groups

**Dose effect** * p=0.038

**CHANGE-MS**

<table>
<thead>
<tr>
<th>Group</th>
<th>Median % reduction at week 48</th>
<th>Relative reduction of atrophy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>-1.27</td>
<td></td>
</tr>
<tr>
<td>18mg/kg</td>
<td>-0.36</td>
<td>72%</td>
</tr>
</tbody>
</table>

Dose effect* p=0.014

**ANGEL-MS**

<table>
<thead>
<tr>
<th>Group</th>
<th>Median % reduction at week 48</th>
<th>Relative reduction of atrophy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>-3.24</td>
<td>43%</td>
</tr>
<tr>
<td>6mg/kg</td>
<td>-2.31</td>
<td>19%</td>
</tr>
<tr>
<td>12mg/kg</td>
<td>-1.70</td>
<td>-9%</td>
</tr>
<tr>
<td>18mg/kg</td>
<td>-1.86</td>
<td></td>
</tr>
</tbody>
</table>

Dose effect* p=0.038

* Dose-effect analyzed by linear regression model

June 2019
Continued reduction Thalamic atrophy
Sensitivity analysis by Dose and by Exposure

**BY DOSE**

<table>
<thead>
<tr>
<th>Group</th>
<th>Median % reduction at week 48 in ANGEL-MS</th>
<th>Relative reduction of atrophy</th>
</tr>
</thead>
<tbody>
<tr>
<td>6mg/kg</td>
<td>-2.7</td>
<td></td>
</tr>
<tr>
<td>12mg/kg</td>
<td>-2.3</td>
<td>17%</td>
</tr>
<tr>
<td>18mg/kg</td>
<td>-1.9</td>
<td>30%</td>
</tr>
</tbody>
</table>

* Dose-effect analyzed by linear regression model

**Dose effect* p=0.03**

**BY EXPOSURE**

<table>
<thead>
<tr>
<th>Group</th>
<th>Median % reduction at week 48 in ANGEL-MS</th>
<th>Relative reduction of atrophy</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1 MIN</td>
<td>-2.3</td>
<td></td>
</tr>
<tr>
<td>G4 MAX</td>
<td>-1.6</td>
<td>30%</td>
</tr>
</tbody>
</table>

* Dose-effect analyzed by linear regression model

**Dose effect* p=0.04**
Continued reduction of Cortex atrophy
Original CHANGE-MS Groups

Percentage Change in Brain Volume from baseline CHANGE-MS to ANGEL-MS Week 48 in Cerebral Cortical Volume

<table>
<thead>
<tr>
<th>Group</th>
<th>Median % reduction at week 48</th>
<th>Relative reduction of atrophy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>-0.59</td>
<td></td>
</tr>
<tr>
<td>18mg/kg</td>
<td>-0.41</td>
<td>31%</td>
</tr>
</tbody>
</table>

Dose effect* p=0.045

<table>
<thead>
<tr>
<th>Group</th>
<th>Median % reduction at week 48</th>
<th>Relative reduction of atrophy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>-1.29</td>
<td>42%</td>
</tr>
<tr>
<td>6mg/kg</td>
<td>-1.27</td>
<td>41%</td>
</tr>
<tr>
<td>12mg/kg</td>
<td>-1.29</td>
<td>42%</td>
</tr>
<tr>
<td>18mg/kg</td>
<td>-0.75</td>
<td></td>
</tr>
</tbody>
</table>

Dose effect* p=0.058

* Dose-effect analyzed by linear regression model

June 2019
Consistent benefit with temelimab seen in non-active population is a key asset

- Median change in volume in non-active population* in CHANGE-MS 18mg/kg versus Control Group

- Effects of temelimab on OPCs and microglia are not due to immune modulation
- Suggests temelimab monotherapy could effectively target neurodegeneration and promote regeneration in non-active populations
- Suggests temelimab as adjunct to highly-effective DMTs for all forms of active MS

* defined as patients without Gd+ activity at baseline

Source: H.P. Hartung et al, ECTRIMS 2018 Presentation
June 2019
Reduction in the number and volume of new T1 hypointense lesions (Black Holes) through CHANGE-MS and ANGEL-MS

### CHANGE-MS Week 48

**Mean Number of Qualifying BH Lesions* (95% CI)**

<table>
<thead>
<tr>
<th>New Qualifying BH</th>
<th>18mg</th>
<th>12mg</th>
<th>6mg</th>
<th>Control group</th>
</tr>
</thead>
</table>

- 18mg: -63% (p=0.014)
- 12mg: -
- 6mg: -
- Control group: -

* T1 hypointense lesion ≥ 14mm³ volume

### ANGEL-MS Week 96

**Group** | **Median percent increase in T1 hypointense lesion volume**
---|---
18mg/kg | 8.7%
12mg/kg | 9.2%
6mg/kg | 14.5%
Control Group | 21.3%

**The set-up of ANGEL-MS did not allow to differentiate acute and chronic T1-hypointense lesions, therefore data not directly comparable to CHANGE-MS measure of chronic lesions**
Reduction in risk of lesions at baseline transforming into new T1Black Holes at CHANGE-MS Week 48

Proportion of patients with T1Gd+ lesions at baseline

Control Group | Temelimab 18mg/kg
---|---
N=33 | N=23

Proportion of patients with non-enhancing T2 lesions at baseline

Control Group | Temelimab 18mg/kg
---|---
N=64 | N=61

Proportion of patients with T1Gd+ lesions transformed into new T1 BHs at week 48

- 58% in Control Group vs. 30% in Temelimab group

Proportion of patients with non-enhancing T2 lesions transformed into new T1 BHs at week 48

- 36% in Control Group vs. 21% in Temelimab group

June 2019
Temelimab preserves myelin integrity over 96 weeks
Normal Appearing White Matter - Original CHANGE-MS Groups

<table>
<thead>
<tr>
<th>Change in MTR signal from CHANGE-MS BL (% units)</th>
<th>18 mg</th>
<th>12 mg</th>
<th>6 mg</th>
<th>Control</th>
<th>Gain 18 vs 12</th>
<th>Gain 18 vs 6</th>
<th>Gain 18 vs Ctrl</th>
<th>Trend p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAWM Band 1 mean</td>
<td>-0.84</td>
<td>-3.02</td>
<td>-3.76</td>
<td>-3.17</td>
<td>2.18</td>
<td>2.91</td>
<td>2.33</td>
<td>0.022</td>
</tr>
<tr>
<td>NAWM Band 1 median</td>
<td>-1.83</td>
<td>-3.55</td>
<td>-3.39</td>
<td>-3.52</td>
<td>1.72</td>
<td>1.56</td>
<td>1.69</td>
<td></td>
</tr>
<tr>
<td>NAWM Band 2 mean</td>
<td>-0.12</td>
<td>-2.17</td>
<td>-2.94</td>
<td>-2.13</td>
<td>2.05</td>
<td>2.82</td>
<td>2.01</td>
<td>0.034</td>
</tr>
<tr>
<td>NAWM Band 2 median</td>
<td>-0.99</td>
<td>-2.70</td>
<td>-2.16</td>
<td>-2.65</td>
<td>1.71</td>
<td>1.17</td>
<td>1.66</td>
<td></td>
</tr>
<tr>
<td>NAWM Band 3 mean</td>
<td>0.74</td>
<td>-1.31</td>
<td>-1.85</td>
<td>-1.11</td>
<td>2.05</td>
<td>2.60</td>
<td>1.86</td>
<td>0.048</td>
</tr>
<tr>
<td>NAWM Band 3 median</td>
<td>-0.32</td>
<td>-1.42</td>
<td>-0.86</td>
<td>-1.35</td>
<td>1.10</td>
<td>0.54</td>
<td>1.03</td>
<td></td>
</tr>
</tbody>
</table>

* Dose-effect analyzed by linear regression, SAS analysis proc GLM

June 2019
Temelimab preserves myelin integrity over 96 weeks
Cerebral Cortex - Original CHANGE-MS Groups

<table>
<thead>
<tr>
<th>Change in MTR signal from CHANGE-MS BL (% units)</th>
<th>18 mg</th>
<th>12 mg</th>
<th>6 mg</th>
<th>Control</th>
<th>Gain 18 vs 12</th>
<th>Gain 18 vs 6</th>
<th>Gain 18 vs Ctrl</th>
<th>Trend p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC Band 2</td>
<td>mean</td>
<td>0.77</td>
<td>-1.24</td>
<td>-1.24</td>
<td>-1.01</td>
<td>2.01</td>
<td>2.01</td>
<td>1.78</td>
</tr>
<tr>
<td></td>
<td>median</td>
<td>0.00</td>
<td>-0.89</td>
<td>-0.73</td>
<td>-0.96</td>
<td>0.89</td>
<td>0.73</td>
<td>0.96</td>
</tr>
<tr>
<td>CC Band 3</td>
<td>mean</td>
<td>0.63</td>
<td>-1.40</td>
<td>-1.42</td>
<td>-1.19</td>
<td>2.03</td>
<td>2.06</td>
<td>1.82</td>
</tr>
<tr>
<td></td>
<td>median</td>
<td>-0.01</td>
<td>-0.97</td>
<td>-1.07</td>
<td>-1.20</td>
<td>0.96</td>
<td>1.06</td>
<td>1.19</td>
</tr>
<tr>
<td>CC Band 4</td>
<td>mean</td>
<td>0.44</td>
<td>-1.76</td>
<td>-1.78</td>
<td>-1.54</td>
<td>2.20</td>
<td>2.22</td>
<td>1.98</td>
</tr>
<tr>
<td></td>
<td>median</td>
<td>0.13</td>
<td>-1.11</td>
<td>-1.12</td>
<td>-1.41</td>
<td>1.24</td>
<td>1.25</td>
<td>1.54</td>
</tr>
</tbody>
</table>

* Dose-effect analyzed by linear regression, SAS analysis proc GLM

June 2019
Lower probability for confirmed disability progression observed - Original CHANGE-MS Groups

<table>
<thead>
<tr>
<th></th>
<th>18 mg/kg</th>
<th>12 mg/kg</th>
<th>6 mg/kg</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of patients with 12-week confirmed worsening in neurological disability from CHANGE-MS baseline to week 48 ANGEL-MS</td>
<td>3.8</td>
<td>4.8</td>
<td>8.3</td>
<td>9.1</td>
</tr>
</tbody>
</table>

Lower probability of 12-week confirmed disability progression in the 18 mg/kg group, but not reaching statistical significance:

- Survival Wilcoxon overall test $p=0.34$
- Log-rank overall test $p=0.45$
- Hazard ratio 18mg/kg vs control = 0.50, pairwise comparison $p=0.27$

June 2019
### Encouraging signs of clinical benefit on Timed 25-Foot Walk

Original CHANGE-MS groups and Sensitivity analyses

<table>
<thead>
<tr>
<th>Timed 25-foot walk – Original CHANGE-MS Groups</th>
<th>18 mg/kg</th>
<th>12 mg/kg</th>
<th>6 mg/kg</th>
<th>Control</th>
<th>P-value**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of patients with worsening ≥ 20% in the Timed 25-Foot Walk Test compared to CHANGE-MS Baseline*</td>
<td>2.4</td>
<td>23.1</td>
<td>13.3</td>
<td>10.2</td>
<td>0.03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Timed 25-foot walk – By Dose Groups</th>
<th>18 mg/kg</th>
<th>12 mg/kg</th>
<th>6 mg/kg</th>
<th>P-Value**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of patients with worsening ≥ 20% in the Timed 25-Foot Walk Test compared to CHANGE-MS Baseline*</td>
<td>3.6</td>
<td>16.9</td>
<td>15.0</td>
<td>0.04</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Timed 25-foot walk – By 18 vs Others</th>
<th>18 mg/kg</th>
<th>Others</th>
<th>P-value**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of patients with worsening ≥ 20% in the Timed 25-Foot Walk Test compared to CHANGE-MS Baseline*</td>
<td>2.4</td>
<td>15.0</td>
<td>0.03</td>
</tr>
</tbody>
</table>

*Fifteen outliers (patients with extreme walking disability) removed from analysis – excluded patients distributed equally across treatment groups

**Fisher exact test
Temelimab was safe and well tolerated over two years.

<table>
<thead>
<tr>
<th>Number of patients (%)</th>
<th>18 mg/kg (N=77)</th>
<th>12 mg/kg (N=68)</th>
<th>6 mg/kg (N=74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Events (AEs)</td>
<td>34 (44.2%)</td>
<td>32 (47.1%)</td>
<td>33 (44.6%)</td>
</tr>
<tr>
<td>Serious adverse events (SAEs)</td>
<td>5 (6.5%)</td>
<td>1 (1.5%)</td>
<td>6 (8.1%)</td>
</tr>
<tr>
<td>Serious related AEs</td>
<td>3 (3.9%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AEs leading to study discontinuation</td>
<td>2 (2.6%)</td>
<td>1 (1.5%)</td>
<td>1 (1.4%)</td>
</tr>
<tr>
<td>Fatality*</td>
<td>1 (1.3%)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* Patient had previously voluntarily exited the study; the Investigator considered the event as unrelated.
Efficacy findings are supported by preclinical data

Clinical observations

- Reduction of Brain Atrophy
- Reduction in new T1 Black Holes
- Benefit on Magnetization Transfer Ratio
- Effects on markers associated with disease progression not due to immune modulation
- Promising a novel treatment option against neurodegeneration in all forms of MS

Supporting pre-clinical data

- Neurodegeneration reduced by: directly acting on proinflammatory microglia, the key immune cells in PMS, responsible for lesion growth and exacerbation
- Neuroregeneration enabled by: rescuing the negative impact of pHERV-W Env on OPC maturation - the key cells in the remyelination process.
- No direct effect on T/B lymphocytes and thereby not compromising adaptive immunity
- Excellent preclinical safety package based on a stabilized IgG4 backbone, low immunogenicity and a linear PK at all doses

Temelimab positioning in MS
Objective: develop a new treatment effective against non-active disease progression

Distinction recently clarified by the FDA

“Active SPMS is one of the relapsing forms of MS, and drugs approved for the treatment of relapsing forms of MS can be used to treat active SPMS. Later, many patients with SPMS stop experiencing new relapses, but disability continues to progress, a phase called non-active SPMS.”

FDA Press release on Siponimod approval, March 26, 2019
GeNeuro Offers a Unique, Unencumbered Opportunity in MS…

**Treatment Landscape**

- **Targeting Inflammation**
  - Relapsing Remitting MS (RRMS)
  - Active Progressive MS (APMS)
  - Immuno-modulators
  - ABCRs Approved for RRMS
  - Orals and Injectables Approved for RRMS
  - Orals and Injectables approved for RRMS AND APMS
- **Targeting Neurodegeneration**
  - Non-Active Progressive MS
  - mAbs
  - Targeting LINGO-1
  - Targeting pHERV-W Env
  - Others
  - Repurposed

**Market Size**

$22bn market in 2018, attributable almost exclusively to inflammation-targeting treatments

*Highly competitive segment: 2018 was the first year with a decrease in total market for immuno-modulators*

*NO DRUG APPROVED*

~30% of MS population

*Very high impact on quality of life*

*Highest unmet medical need*

Sources: EvaluatePharma, Annual reports of companies active in MS

June 2019
### Drugs in development that specifically target neurodegeneration

<table>
<thead>
<tr>
<th>Drug</th>
<th>Company</th>
<th>Pharmacology</th>
<th>Proposed Mode of Action</th>
<th>Dev. Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opicinumab</td>
<td>Biogen</td>
<td>Monoclonal antibody IgG1 neutralizing LINGO-1 protein</td>
<td>Favoring oligodendrocyte differentiation and remyelination</td>
<td>Ongoing Phase IIb</td>
</tr>
<tr>
<td>Biotin</td>
<td>MedDay</td>
<td>Vitamin B8/H given at high dose (300mg/day)</td>
<td>Increasing energy supply (ATP, fatty acid) to oligodendrocytes favoring myelin production</td>
<td>Ongoing Phase 3</td>
</tr>
<tr>
<td>Ibudilast</td>
<td>MediciNova</td>
<td>Anti-inflammatory drug, approved in Japan for asthma since 1989</td>
<td>Inhibition of macrophage migration, decrease of TNFα, enhancing survival and maturation of oligodendrocytes</td>
<td>Completed Phase IIb</td>
</tr>
<tr>
<td>Masitinib</td>
<td>AB Science</td>
<td>Selective tyrosine kinase inhibitor developed in neurology, inflammatory diseases and oncology</td>
<td>Inhibiting mast cell degranulation to avoid proteolysis, secretion of vasoamines and release of pro-inflammatory chemoattractants</td>
<td>Phase III ongoing</td>
</tr>
<tr>
<td>Temelimab</td>
<td>GeNeuro</td>
<td>Monoclonal antibody IgG4 neutralizing pHERV-W-Env, associated to MS as a causal factor</td>
<td>Enhancing remyelination and reducing damage by promoting OPC maturation and blocking microglial activation</td>
<td>Completed Phase IIb</td>
</tr>
</tbody>
</table>

Sources: Mellion et al., Neurology 2017; Kremer et al., MSJ 2018 In print; Green et al., Lancet 2017; Company web sites
The ANGEL-MS results further support development of temelimab to prevent disease progression in MS

- Disease progression remains the key unmet medical need in MS
  - “The greatest remaining challenge for multiple sclerosis is the development of treatments incorporating neuroprotection and remyelination to treat and ultimately prevent the disabling, progressive forms of the condition.”
    Prof. Alan J Thompson, Lancet 2018; 391: 1622–36

- Development plan
  - As monotherapy, in non-active Progressive MS patients, where the unmet medical need is the highest
  - In combination with an existing anti-inflammatory drug, to slow-down / prevent progression on treated Relapsing MS patients (rendered “non-active” by their inflammatory treatment), an area in which current treatments have modest impact

- GeNeuro is fully committed to further develop temelimab in MS
Part 2

Temelimab in T1D
Overview of Type 1 Diabetes

- Type 1 Diabetes is a **chronic disease** associated with autoimmunity that results from the destruction of pancreas’ insulin-producing beta cells.
- Represents 5-10% of total diabetes cases (est. >4-6 million worldwide)
- Prevalence of T1D is approximately 1 in 300 in the US by 18 years of age.
- 85% of all T1D diabetes cases have an onset in people under 20 years-old
- Treatments focused on managing glycaemia by insulin injections
- $6.6bn worldwide sales in 2013; Market growth driven by approval of T2D drugs for T1D (GLP-1s RAs and SGLT-2 inhibitors)

- **No disease modifying therapies** available today
- Several debilitating complications associated with insulin replacement, a life-long treatment
  - >50% of adults with T1D have an A1C >8%
  - Severe consequences of poor glucose level control include renal, ophthalmic, cardiac, vascular and nervous system dysfunctions and deficiencies
  - Significant risk of coma and death by hyperglycemia or hypoglycemia
- Preservation of remaining insulin production:
  - Residual β-cell function may prevent ketoacidosis for many years
  - Preservation of endogenous insulin production is the best prognosis against T1D co-morbidities

Sources: NIH - Genetics Home reference; JDRF.org; WHO; Endocrinol Metab Clin North Am. D. Maahs et al., 2010

June 2019
Data support the hypothesis of a causal role of pHERV-W Env in T1D

- Found in the pancreas of over 70% of T1D patients post-mortem. About 60% in blood.

- Dose dependent disruption of insulin production in vitro by pHERV-W Env

- Induction of hyperglycemia and hypoinsulinemia by pHERV-W Env protein in young HERV-W env transgenic mice

- Preliminary results show that Coxsackie virus type B 4E2 strain upregulates pHERV-W Env expression

Sources: An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes, S. Levet et al., JCI Insights, September 2017; JDRF/nPOD 2017 Meeting, Fort Lauderdale, USA. ADA 2017 meeting, San Diego, USA.

June 2019
RAINBOW-T1D: Phase IIa to assess safety and pharmacodynamics in an adult T1D population

- A 6-month double-blind placebo-controlled study to assess safety and pharmacodynamics in an adult T1D population;
  - Double Blind Period Weeks 1-24: 1 active (temelimab 6mg/kg) group vs. placebo
  - Open Label Period Weeks 25-48: 1 active dose group (placebo patients switched to temelimab)
- 64 male and female patients, 18–55 years, with T1D diagnosed in the 4 years prior to signed ICF
- Peak stimulated C-peptide of $\geq 0.2\,\text{nmol/L}$; HbA1c $< 9\%$; $>1$ diabetes-associated auto-antibody

![Diagram of study design](image-url)

Legend:
- MMTT + C-peptide
- T1D Antibodies

* End of study Visit performed once, either after double-blind or open-label period

June 2019
**Week 48 Safety Outcomes in adult T1D population**

Temelimab remains is very well tolerated over 48 weeks

<table>
<thead>
<tr>
<th></th>
<th>Temelimab/temelimab (N=12)</th>
<th>Temelimab/temelimab (N=31)</th>
<th>Placebo/temelimab (N=7)</th>
<th>Placebo/temelimab (N=14)</th>
<th>Overall (N=64)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serious adverse events (SAEs)</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Serious related AEs</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1*</td>
<td>1</td>
</tr>
<tr>
<td>Number of patient with at least one AE (%)</td>
<td>10 (83.3%)</td>
<td>28 (90.3%)</td>
<td>6 (85.7%)</td>
<td>13 (92.9%)</td>
<td>57 (89.1%)</td>
</tr>
<tr>
<td>AEs leading to early termination</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>AEs leading to death</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*headache occurring during the placebo period
Week 48 PD Outcomes - Hypoglycemia
Confirmed decrease of hypoglycemic episodes

<table>
<thead>
<tr>
<th>Adjusted mean number of hypoglycemic episodes per patient</th>
<th>Temelimab/temelimab (N=31 out of 43**)</th>
<th>Placebo/temelimab (N=14 out of 21**)</th>
<th>Rate ratio</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double-blind Period</td>
<td>2.09</td>
<td>2.92</td>
<td>0.75</td>
<td>0.0001</td>
</tr>
<tr>
<td>Extension Period</td>
<td>1.88</td>
<td>2.07</td>
<td>0.91</td>
<td>0.82</td>
</tr>
</tbody>
</table>

Group treated by temelimab 12 months:
- Reduction of frequencies of hypoglycemia under temelimab in first 6-month (-28%, p<0.0001 vs placebo),
- Further reduction of 10% in the second 6 month period

Group switching to temelimab from placebo:
- Reduction of hypoglycemia frequency in this group vs the previous placebo period (-29%), reaching the level of reduction observed with temelimab in the first 6 months of treatment

* Poisson regression analysis
** Patients who continued in the Open-Label period

June 2019
RAINBOW-T1D Summary
Successful study, opening way to early-onset T1D trials

• 12 month study with a 6-month double blind period and a 6-month extension with all patients on temelimab, including patients previously on placebo

• Excellent safety / tolerability of temelimab observed over one year

• Positive temelimab pharmacodynamic observations at 6 months are confirmed in the second period

• No conclusions possible on C-peptide, insulin consumption and HbA1C: small cohort size from a late onset adult population, well treated with low insulin needs, stable during trial

• Study completes its objective of demonstrating safety and pharmacodynamic response in adult T1D patients, opening door to further development in larger early-onset pediatric population
Part 3

GeNeuro development in ALS
HERV-K Env is upregulated in ALS, and toxic to neurons

- HERV-K (HML-2) is expressed significantly higher in brain tissue of ALS patients than in healthy controls or other neurological disorders.

- Expression of HERV-K in neurons is toxic.

- Genetic investigations reveal that there is dysregulation of HERV-K in a subset of patients with sporadic ALS.


June 2019
In vivo validation of the HERV-K concept in ALS through transgenic mice

- NINDS developed a transgenic mouse that expresses HERV-K Env in the brain and spinal cord (neurons)

- The phenotype of the transgenic mouse mimics signs and symptoms of clinical ALS


June 2019
Status of the ALS project

• Research partnership in 2017 with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH)
  • GeNeuro provides antibodies designed to block the activity of HERV-K envelope protein
  • NINDS tests antibodies in cellular and animal models of HERV-K associated ALS
  • Results validate the potential of GeNeuro’s anti pHERV-K antibodies as a new therapeutic approach against ALS

• Following successful results of the research partnership with NIH in ALS models, GeNeuro has signed in October 2018 an exclusive worldwide license with the NIH covering the development rights of an antibody program to block the activity of pHERV-K Env, a potential key factor in the development of ALS

• GeNeuro has launched the preclinical development of the lead antibody, aiming at IND by mid-2020
Part 4

Good basis for growth
The GeNeuro team

Jesús Martin-Garcia | MBA
Chief Executive Officer – Co-founder

Strong track-record in creating value in high technology start-ups

More than 20 years of experience as founder and investor in successful startups

MBA from Harvard Business School

Dr. François Curtin | MD, MPhil, MBA
Chief Operating Officer

15 years experience in MS, in charge of R&D and clinical development

Clinical expertise at Merck Serono, previously at Swissmedic (“Swiss FDA”)

MD from Geneva Medical School & MBA from Warwick Business School

Dr. Hervé Perron | PhD, HDR
Chief Scientific Officer – Co-founder

Made the initial key discoveries in the field of human endogenous retroviruses while at INSERM and bioMérieux

Has published over 120 peer-reviewed papers and patents, mostly on HERVs

PhD in virology and a professorial thesis in neuroimmunology

Dr. Robert Glanzman | MD
Chief Medical Officer

Over 20 years of clinical, medical affairs and clinical development experience in MS

13 years as Medical Affairs/Clinical Development Leader at Pfizer, Novartis and Roche. Global Development Lead for Ocrelizumab Phase III

MD with Residency in Neurology from the University of Michigan

Dr. Thomas Rückle | PhD, PMP
SVP, Head of Preclinical Development

Over 20 years experience in translational science

Preclinical and early clinical expertise at Merck Serono & MMV. As project director, led several projects from lead to Phase II clinical proof of concept

PhD in Organic Chemistry

Miguel Payró
Chief Financial Officer

Experience in international groups & expertise as CFO of a Swiss listed company in the medical sector

Previously CFO of Groupe Franck Muller & Unilabs, among others

Degree in business administration from the University of Geneva
Financial Summary

Share capital as of May 2019

P&L and cash balance (in € ‘000)

<table>
<thead>
<tr>
<th></th>
<th>1Q 2019</th>
<th>FY 2018</th>
<th>FY 2017</th>
<th>FY 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income</td>
<td>n.a.</td>
<td>7,463</td>
<td>14,949</td>
<td>5,918</td>
</tr>
<tr>
<td>R&amp;D Expenses</td>
<td>n.d.</td>
<td>(10,930)</td>
<td>(16,161)</td>
<td>(14,419)</td>
</tr>
<tr>
<td>Operating loss</td>
<td>n.d.</td>
<td>(8,089)</td>
<td>(5,740)</td>
<td>(14,037)</td>
</tr>
<tr>
<td>Cash &amp; Equivalents</td>
<td>13,300**</td>
<td>16,461**</td>
<td>26,602</td>
<td>34,489</td>
</tr>
</tbody>
</table>

Notes: * 2016: includes €1,801k of IPO-related fees
** : pro forma, including €7.5 mln line of credit facility with GNEH SAS established Dec. 2018 – of which €2.5 mln was drawn at end of 1Q

June 2019

Note: excludes stock options and performance-based option units, representing a maximum 6.9% dilution, with an average exercise price of €10.38 per share.
Value enhancing milestones in early 2019

✓ Phase Ic testing higher doses of temelimab for further development 1Q2019

✓ ANGEL-MS (2 year results) 1Q2019

✓ T1D Phase Ila full 12-month results 2Q2019

• Partnership discussions on temelimab in MS
Capturing the full value of the HERV platform

• Cash to deliver on ongoing programs – funded mid-2020
  • MS: ANGEL-MS results – Phase Ic testing safety of higher doses of temelimab
  • T1D: 12-month results of RAINBOW trial with temelimab
  • ALS: preclinical development of new monoclonal antibody against pHERV-K

• Open options for development going forward in MS
  • Partnering discussions ongoing
  • Confirmatory trial to find optimal dose in target non-active progressive population, potentially supporting registration

• Open options for development in other indications, alone or with partners
  • Phase IIb in T1D in a juvenile population
  • IND for anti pHERV-W new monoclonal antibody planned for mid-2020
Targeting the cause of neurodegenerative and autoimmune diseases

Jesús Martin-Garcia | CEO
jmg@geneuro.com
Tel: +41 22 552 4800